Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 16;29(5):e601–e615. doi: 10.1093/oncolo/oyae007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Median PFS with FTD/TPI-containing combination regimens in patients with metastatic colorectal cancer in second- or third-line settings. *Median PFS was 3.7 by central assessment and 5.6 months by investigator assessment. **Data pertain to patients receiving FTD/TPI ± BEV. ^†Median PFS was 2.2 months per immune-related response criteria and 2.8 months per response evaluation criteria in solid tumors (RECIST). Abbreviations: 2L, second line; 3L, third line; BEV, bevacizumab; chemo, chemotherapy; FTD/TPI, trifluridine/tipiracil; IRI, irinotecan; NA, not applicable; NIN, nintedanib; NIVO, nivolumab; OXA, oxaliplatin; PAN, panitumumab; PFS, progression-free survival; REG, regorafenib.